Love Pharma launches exclusive e-commerce platform for online sales

  • Launch of LOVE’s online store with a fully integrated e-commerce platform
  • Consumers can now purchase the company’s two proprietary branded products, BLOOM and Auralief, establishing a strong plug-and-play online retail presence for existing and upcoming Love Pharma products.
  • Online platform seamlessly integrates social media and digital marketing capabilities for sales and marketing campaigns

VANCOUVER, BC / ACCESSWIRE / September 21, 2022 / LOVE Pharma Co. (“LOVE” and/or “The Company”) (CSE:LUV)(FSE:G1Q0)the company is delighted to announce the launch of the Love Pharma online store, a fully integrated e-commerce platform showcasing its exclusive products, BLOOM and Auralief, now available for purchase on

“This exclusive online store will be rolled out for LOVE’s over-the-counter therapeutic arm, for which the company holds 6 exclusive licenses, as previously announced,” said Mr. Joshua Maurice, COO of LOVE. “During the initial phase of soft launch, we are focusing on direct-to-consumer sales, supported by integrated social media and digital marketing campaigns. The second phase of B2B sales will build on the success of our strategies B2C marketing and outreach. We constantly evaluate the results to establish the most effective B2B launch using our proprietary e-commerce platform.”

Technology infrastructure and applications were launched to leverage social media and digital campaigns, driving consumers to individual landing pages for Bloom and Auralief products. The customer experience is designed to work seamlessly, connecting consumers directly to the online store where products can be purchased at: and,

As a result of this progression, the Company now has the ability to generate revenue from sales of Bloom and Auralief, noting that there are no guarantees tied to revenue. Proprietary e-commerce technology may also be deployed with additional products as over-the-counter offerings evolve in the future. It should be noted that the Company holds 6 exclusive licenses for therapeutic products in the wellness area. Management is delighted to have reached this important milestone by launching its highly anticipated over-the-counter consumer therapeutics division.

In regards to the company’s announcement on September 7, 2022, Love Pharma has made a strategic investment in Starton Therapeutics but does not have a formal relationship or strategic alliance with Starton at this stage, but aims to develop opportunities to work together in the future. Love Pharma’s investment in Starton Therapeutics is primarily based on the company’s interest in innovative drug delivery technologies, such as transdermal patches, which can reduce side effects, transforming patient outcomes with medication. established and approved allowing easy market entry with long-term IP protections.

Mr. Maurice said, “Love Pharma is pleased to leverage its strategic investment in Starton. While there is no promise or guarantee as to the outcome of the investment for Love Pharma investors, there is a significant opportunity for the company given the robust catalog of intellectual property and innovation, Starton has grown diligently and continues to progress.”

The company also announces that it has entered into contractual agreements for marketing, communications, shareholder engagement, market making and social media communications. The marketing and communications program will include certain investor relations activities and is designed to provide greater visibility of the Company’s current and planned operations. The Company entered into agreements with Penny Lane Consultants for a period of 4 months for a total of 84,267.25 USD.

Zachary Stadnyk, CEO and Director

About Love Pharma Inc.

Focusing on the global sexual health and wellness markets, Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) was founded in 2020, with a mission to bring to market innovative products that improve sexual health and well-being while providing a better quality of life. Love Pharma holds exclusive licenses to produce, package, sell and distribute patent protected pharmaceutical and therapeutic products across Europe, UK and North America.

For more information, please contact:

Investor Relations
Telephone: 1 (604) 343-2977
E-mail: [email protected]

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this release may constitute “forward-looking statements” or “forward-looking information” (collectively “forward-looking information”) as such terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “plan”, “estimate”, “anticipate” and expressions and similar statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current beliefs or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the Company’s business, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. except as required by securities laws. Due to the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

THE SOURCE: Love Pharma Inc.